Genomic Profiling of Breast Cancers a Better Treatment Tool

(Page 2)

The study was published in the April 2 issue of the Journal of the American Medical Association.

This study "demonstrates the potential value of using microarray-based gene signatures to refine outcome predictions," Chiang-Ching Huang and Markus Bredel, of the Feinberg School of Medicine at Northwestern University in Chicago, wrote in an accompanying editorial.

"In an attempt to tailor risk estimation, these investigators shy away from pure metagene predictors but instead focus on genes with mechanistic implication in breast cancer. Because these genes represent potential targets for specific molecular therapy, this approach represents an advance in the changing landscape of oncology toward individualized patient management," they wrote.

More information

The American Cancer Society has more about breast cancer.